Oculis Holding AG
Clinical-stage biopharma developing therapies for ophthalmic and neuro-ophthalmic diseases.
OCS | IC
Overview
Corporate Details
- ISIN(s):
- CH1242303498 (+1 more)
- LEI:
- 5067005370C2KK324336
- Country:
- Switzerland
- Address:
- Bahnhofstrasse 7, 6300 Zug
- Website:
- https://www.oculis.com/
- Sector:
- Manufacturing
Description
Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-09 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 951 bytes | ||
| 2025-12-03 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 949 bytes | ||
| 2025-11-28 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 949 bytes | ||
| 2025-11-18 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 948 bytes | ||
| 2025-11-10 22:05 |
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri …
|
Icelandic | 21.9 KB | ||
| 2025-11-10 22:05 |
Oculis Reports Q3 2025 Financial Results and Provides Company Update
|
English | 19.2 KB | ||
| 2025-11-05 10:00 |
Oculis to Participate in Upcoming November Investor Conferences
|
English | 8.4 KB | ||
| 2025-10-30 09:17 |
Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað …
|
Icelandic | 12.9 KB | ||
| 2025-10-30 09:17 |
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegto…
|
English | 12.1 KB | ||
| 2025-10-14 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 1.2 KB | ||
| 2025-10-14 10:00 |
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO …
|
English | 15.5 KB | ||
| 2025-10-08 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 949 bytes | ||
| 2025-10-06 10:07 |
Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugab…
|
Icelandic | 18.7 KB | ||
| 2025-10-06 10:07 |
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neurit…
|
English | 16.8 KB | ||
| 2025-09-26 22:05 |
Oculis Publishes Notification of Transactions by Person Discharging Managerial …
|
English | 1.0 KB |
Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oculis Holding AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oculis Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
